Pleural fluid biomarker testing to help diagnose lung adenocarcinoma
Official title: Novel Pleural Effusion Biomarkers Screening and Evaluation in Lung Adenocarcinoma Patients
Run by Fu Jen Catholic University · NCT07012759 · Data updated 2026-11-12
This project will test whether measuring new molecular markers in pleural fluid can help diagnose lung adenocarcinoma in adults who need thoracentesis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Fu Jen Catholic University Academic / other |
| Locations | 1 site (New Taipei City) |
| Status | Recruiting |
| Started | June 10, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | March 5, 2026 |
| Trial ID | NCT07012759 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults who require thoracentesis for pleural effusion and who consent to provide samples, particularly those with suspected or confirmed lung adenocarcinoma, are ideal candidates.
✕Probably not a fit
Patients under 18, people with pleural effusions caused by cancers other than lung adenocarcinoma, and individuals not undergoing thoracentesis are unlikely to receive direct benefit from this observational biomarker study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a two-year, single-center prospective case-control study conducted at Fu Jen Catholic University Hospital. The investigators will collect about 100 pleural effusion samples from patients with malignant and non-malignant causes who undergo clinically indicated thoracentesis. After centrifugation, both the supernatant and the sedimented cells will be analyzed for expression of candidate genes and concentrations of secreted proteins previously identified in lung cancer cell models. Expression levels will be compared between malignant and non-malignant samples to determine whether the markers can distinguish lung adenocarcinoma-related effusions.
Why it matters
Potential benefit: If successful, these biomarkers could enable more accurate, less invasive diagnosis of lung adenocarcinoma from pleural fluid and reduce the need for additional invasive procedures.
How similar studies have gone: Prior biomarker studies on pleural fluid have shown promise for improving diagnosis but many candidate markers remain unvalidated in clinical samples, so this effort builds on preliminary findings rather than established clinical practice.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients requiring thoracentesis for pleural effusion drainage as determined by a physician based on clinical need. * Signed informed consent. Exclusion Criteria: * Patients under the age of 18. * Patients with malignancies other than lung adenocarcinoma.
Where it's running
-
Fu Jen Catholic University Hospital, Fu Jen Catholic University
New Taipei City, Taiwan Recruiting
Study contacts
- Principal investigator: Ke-Yun Chao, PhD — Fu Jen Catholic University
- Study coordinator: Ke-Yun Chao, PhD
- Email: ck_qq@hotmail.com
- Phone: +886905301879
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Feasibility of a disposable flexible bronchoscope for thoracoscopy compared with a semi-rigid pleuroscope in pleural effusion
This study tests whether a single-use flexible bronchoscope can be used safely and effectively for medical thoracoscopy in patients with pleural effusion, compared with the standard semi-rigid pleuroscope.
-
DBC-664 in adults with solid tumors
A first-in-human study will test DBC-664 to see if it is safe and tolerable in adults with various advanced solid tumors and may hint at anti-tumor activity.
-
Ex Vivo Drug Response Testing in Lung Adenocarcinoma with Malignant Pleural Effusions
This study tests whether the way cancer cells from pleural effusions respond to drugs outside the body can predict how patients will respond to treatment.
-
Vortioxetine for cognitive problems in ALK/ROS1-positive NSCLC treated with lorlatinib
This observational study tests whether vortioxetine can help with cognitive and neurological side effects in adults with ALK/ROS1-positive NSCLC who are taking lorlatinib.
-
Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain
This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.
-
7-day low-carb, high-fat (ketogenic) diet to improve FDG PET/CT detection of lepidic lung adenocarcinoma
This trial will test whether a personalized 7-day ketogenic (low-carb, high-fat) diet before an FDG PET/CT can improve detection of lepidic-predominant lung adenocarcinoma in adults with a suspicious lung nodule or confirmed diagnosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.